ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
about
Why do BCL-2 inhibitors work and where should we use them in the clinic?Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways.Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma.Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis
P2860
ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@en
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@nl
type
label
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@en
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@nl
prefLabel
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@en
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer.
@nl
P2093
P2860
P1433
P1476
ABT-737 Synergizes with Cispla ...... in Non-small Cell Lung Cancer
@en
P2093
Eun Young Kim
Se Kyu Kim
P2860
P304
P356
10.1016/J.NEO.2017.02.008
P577
2017-03-17T00:00:00Z